Clinical Trial Update: CCFZ533X2201 - PoC Study in de Novo Renal Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 PoC study in de novo kidney transplantation by Novartis (CCFZ533X2201) has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Failure
• Kidney Transplant
• Kidney Transplant Failure

Drugs mentioned

• CCFZ533X2201

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-12-21